Florian Schenck
Hannover Medical School
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Florian Schenck.
Journal Der Deutschen Dermatologischen Gesellschaft | 2010
Annette Degen; Mareike Alter; Florian Schenck; Imke Satzger; Bernward Völker; Alexander Kapp; Ralf Gutzmer
The hand‐foot‐syndrome (HFS, palmoplantar erythrodysesthesia, chemotherapy‐associated acral erythema) is characterized by painful predominantly palmo‐plantar lesions. The association with different chemotherapeutic agents has been known for over 20 years. More recently, HFS has been reported in association with regimens using targeted agents, in particular the multikinase inhibitors (MKI) sorafenib and sunitinib. The HFS associated with MKI has a different distribution and clinical appearance than the traditional disorder. In this review, similarities and differences between chemotherapy‐ and MKI‐associated HFS are discussed and current recommendations for their prophylaxis and management are summarized.
Dermatology | 2010
Imke Satzger; Uta Küttler; Bernward Völker; Florian Schenck; Alexander Kapp; Ralf Gutzmer
Previously an increased frequency of KIT aberrations in mucosal melanomas was reported, whereas c-KIT in most types of cutaneous melanomas does not appear to be of pathogenetic importance. Imatinib has become the standard of care in other cancers with KIT mutations such as gastrointestinal stromal tumors. Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib. We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
The American Journal of Surgical Pathology | 2007
Imke Satzger; Bernward Völker; Andre Meier; Florian Schenck; Alexander Kapp; Ralf Gutzmer
The detection of micrometastases (defined as groups of malignant cells) in the sentinel lymph node (SLN) is an important prognostic tool in melanoma. The use of immunohistochemistry with melanocytic markers such as HMB45 and Melan A increases the detection rate of micrometastases but there are also cases with isolated immunohistochemically positive cells (IPC). To determine the prognostic significance of isolated HMB45 and/or Melan A positive cells in melanoma SLN, we compared the clinical course of 47 patients with IPC to 308 patients with negative SLN and to 122 patients with micrometastases. The mean follow-up was 38.1 months. By Kaplan-Meier analyses, relapse free survival and overall survival of patients with IPC were similar to SLN negative patients, whereas patients with micrometastases had a significantly worse relapse free survival and overall survival. In the 47 patients with IPC, 6 relapses (12.8%) and 3 melanoma-related death (6.4%) occurred, in the SLN negative patients 36 relapses (11.7%) and 17 melanoma-related deaths (5.5%), in the patients with micrometastases 46 relapses (37.7%) and 29 melanoma-related deaths (23.8%). Prognosis of patients with IPC in SLN did not correlate with type of positive staining (HMB45, Melan A, or both), capsular involvement, number of cells, presence of cytologic atypias of IPC, or tumor penetrative depth. In conclusion, with short-term follow-up IPC in melanoma SLN are without prognostic significance.
International Journal of Cancer | 2007
Imke Satzger; Andre Meier; Florian Schenck; Alexander Kapp; Axel Hauschild; Ralf Gutzmer
Interferon alpha is used for the adjuvant treatment of malignant melanoma at different dosages (high‐, intermediate‐, low‐dose therapy). Only a minority of patients might benefit from this therapy, and markers to identify such patients are missing. A recent study suggested that melanoma patients developing autoantibodies or clinical manifestations of autoimmunity during adjuvant high‐dose interferon alpha treatment had a significant survival benefit. We retrospectively reviewed 134 melanoma patients from our institution treated with adjuvant low‐dose interferon alpha therapy and correlated the development of autoimmune diseases with prognosis. Interferon (IFN) therapy was routinely monitored by history, physical examination and laboratory tests before, after the first month and then after every 3 months of therapy. During a median follow up of 46.0 months (8.5–79.0 months) 28 patients (20.9%) suffered from recurrences and melanoma related deaths occurred in 16 patients (11.9%). In 20 patients (14.9%) autoimmune thyroiditis (AIT) was diagnosed during IFN therapy, one of these 20 patients developed rheumatoid arthritis later while continuing IFN therapy. Other autoimmune diseases were not observed. In 2 patients (one with AIT and one with arthritis) the autoimmune disease led to discontinuation of IFN therapy, in the other patients AIT remained subclinical or responded well to treatment while IFN therapy was continued. Kaplan–Meier analyses revealed a significant better recurrence free survival and a trend for a better overall survival for patients with AIT. Thus, autoimmunity triggered by low‐dose IFN therapy appears to indicate an improved prognosis and should encourage continuation of IFN therapy.
Immunotherapy Open Access | 2017
Uwe Trefzer; Ralf Gutzmer; Tabea Wilhelm; Florian Schenck; Katharina C. Kähler; Volkmar Jacobi; Klaus Witthohn; Hans Lentzen; Peter Mohr
Aviscumine (ME-503), a recombinant lectin, enhances inflammatory cytokine (esp. IL-1β) release, activation of Langerhans cells, and T-cell responses. An extended evaluation of phase II data of the patient cohorts with/without skin reactions within the first treatment cycle after SC injection regarding the efficacy of aviscumine are presented. 31 patients (ITT total population) (ECOG: 0 or 1) with progressive stage IV malignant melanoma after failure of standard therapy were enrolled onto a single-arm, multi-centre, open-label, phase II trial (NCT00658437). Patients received 350 ng aviscumine twice weekly by SC injection until progression. Tumor response was assessed every eight weeks, survival of patients was followed up to one year after the end of therapy. 21 patients with skin reactions vs. 9 patients without skin reactions as adverse events were assessed for efficacy in an expanded evaluation. Comparing the median overall survival data (mOS) in patients (n=9) without injection site reactions (mOS: 5.1 months; 95% CI 2.1-6.9; 1-year survival rate: 0%) with survival data in patients (n=21) showing injection site reactions (mOS: 14.6 months; 95% CI 11.0-19.8; 1-year survival rate: 62%) a clear difference in favor of the patients with skin reactions is seen. The difference in overall survival between these two groups of patients was high significant (p<0.0001). In the total ITT population (n=31) the mOS was 11.0 months (95% CI 6.9-19.8) and the 1- year survival rate was 45%. Preliminary conclusions from our small cohorts suggest a strong clinical impact of aviscumine in patients with previously treated metastatic melanoma if those patients show injection site reactions as adverse events after SC injection within the first treatment cycle. Patients without any injection site reactions apparently failed to prove clinical benefit.
Cancer Research | 2016
Peter Mohr; Uwe Trefzer; Ralf Gutzmer; Tabea Wilhelm; Florian Schenck; Katharina C. Kähler; Volkmar Jacobi; Klaus Witthohn; Hans Lentzen
Background: Aviscumine, a recombinant protein, inactivates the 28S rRNA (“ribotoxic stress”) after endocytosis and enhances inflammatory cytokine (esp. IL-1s) release, activation of Langerhans cells and T-cell responses. Phase II data of the total patient population vs. a small patient cohort with/without skin reactions after SC injection are reported regarding the efficacy of aviscumine in patients with progressive metastatic melanoma stage IV. Methods: 32 pts. (ECOG: 0 or 1) were enrolled onto a single-arm, multi-centre, open-label, phase II trial (NCT00658437). Patients received 350 ng aviscumine twice weekly by SC injection until progression. Tumor response was assessed every eight weeks, survival of patients was followed up to one year after the end of therapy. 30 patients were assessed for overall survival (OS) and skin reactions were monitored as adverse events. Results: The median OS of the 30 patients was 10.7 months; (95% CI 6.4-14.3). The patients had a 1-year survival rate of 43.3%. The patients with an injection side reaction (n = 21) during the first cycle of treatment showed a mOS of 14.6 months (95% CI 11.0 - 19.8) whereas the survival data in patients (n = 9) without injection site reactions were 5.1 months (95% CI 2.1-6.9). No patient in this group without skin reactions survived 1-year. Comparing the 2 groups with / without skin reactions a clear difference in favor of the patients with injection site reactions is seen. High significance (p Conclusion: These results suggest a strong clinical impact of aviscumine in patients with previously treated metastatic melanoma if those patients show injection site reactions as a sign of an immune reaction after SC injection within the first treatment cycle. Patients without any injection site reactions apparently failed to prove clinical benefit. Due to relatively small sample size in this study, these findings require validation in a larger patient cohort. Citation Format: Peter Mohr, Uwe Trefzer, Ralf Gutzmer, Tabea Wilhelm, Florian Schenck, Katharina C. Kahler, Volkmar Jacobi, Klaus Witthohn, Hans Lentzen. Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT123.
Dermatology | 2010
Daniele Torchia; Pietro Cappugi; Tatiana Lamon; Stephane Gerard; Nicolas Meyer; Benjamin Losfeld; Gabor Abellan van Kan; Laurent Balardy; Bruno Vellas; Louise Lovato; Gabriel Salerni; Susana Puig; Cristina Carrera; Josep Palou; Josep Malvehy; M. Ulrich; D. Krueger-Corcoran; J. Roewert-Huber; W. Sterry; E. Stockfleth; S. Astner; F.M. Solivetti; F. Elia; M. Teoli; C. De Mutiis; S. Chimenti; E. Berardesca; A. Di Carlo; Muhammad Wajid; Mazen Kurban
– Angelika Stary (Austria) Sexually Transmitted Infection and Global Migration – Christopher Griffi ths (UK) Psoriasis: More Than One Disease? – Jenny Kim (USA) Acne and Acneiform Diseases (Inducer of Follicular Infl ammation) – John Voorhees (USA) Aging Skin – Jürgen Schauber (Germany) Antimicrobial Peptides: More Than Epidermal Antibiotics – Katsuto Tamai (Japan) Regeneration and Repair – Markus Frank (USA) Stem Cells in Skin Cancer – Miroslav Blumenberg (USA) Skinomics: Molecular Profi ling as a Diagnostic Tool – Seung Hun Lee (Korea) Disorders of the Epidermal Barrier – Stephan Wagner (Austria) Melanoma: Do We Need a New Classifi cation?
Journal Der Deutschen Dermatologischen Gesellschaft | 2007
Imke Satzger; Florian Schenck; Felicitas Thol; Arnold Ganser; Alexander Kapp; Ralf Gutzmer
Erythropoietin has been successfully used in Europe since 1997 in the treatment of anemia induced by chemotherapy of solid tumors. There is only limited experience with regard to its use when treating dermatologic tumors such as metastatic melanoma.We review here current guidelines on the use of erythropoietin in cancer patients and report on our own melanoma patients treated with erythropoietin for chemotherapy‐induced anemia.
European Journal of Dermatology | 2006
Imke Satzger; Florian Schenck; Alexander Kapp; Ralf Gutzmer
Journal for ImmunoTherapy of Cancer | 2014
Uwe Trefzer; Ralf Gutzmer; Tabea Wilhelm; Florian Schenck; Katharina C. Kähler; Volkmar Jacobi; Klaus Witthohn; Hans Lentzen; Peter Mohr